Jiangshan Oupai has appointed Chen Chunjin as the company's board secretary, effective immediately. This move means the company's chairman, Wu Shuigen, will no longer perform the duties of the board secretary. Separately, Huiyu Pharmaceutical's subsidiary, Huiyu Haiyue, has received acceptance from the National Medical Products Administration for its clinical trial application for subcutaneous injection HY07121, a novel biological product designed to treat advanced solid tumors by targeting PD-1, TIGIT, and IL-15/IL-15Rα. AI
RANK_REASON The cluster contains two distinct, unrelated news items: a corporate personnel change and a clinical trial acceptance, neither of which meets the criteria for higher tiers.
- Chen Chunjin
- Huiyu Haiyue
- Huiyu Pharmaceutical
- HY07121
- Jiangshan Oupai
- National Medical Products Administration
- Wu Shuigen
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →